Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

Marijke B. Coomans, Linda Dirven, Neil Aaronson, Brigitta G. Baumert, Martin van den Bent, Andrew Bottomley, Alba A. Brandes, Olivier Chinot, Cornel Coens, Thierry Gorlia, Ulrich Herlinger, Florence Keime-Guibert, Annika Malmström, Francesca Martinelli, Roger Stupp, Andrea Talacchi, Michael Weller, Wolfgang Wick, Jaap C. Reijneveld, and Martin J. B. Taphoorn, on behalf of the EORTC Quality of Life Group and the EORTC Brain Tumor Group

Abstract

Background. Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period.

Methods. We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period.

Results. Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9–29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8–5.4 months, and median
Adult patients with a malignant glioma are confronted with the outlook of a limited survival span, along with an increasing symptom burden. The incurable nature of gliomas has led to the recognition that maintenance or improvement of health-related quality of life (HRQoL) is one of the main treatment goals in this patient group. Although the results of most randomized controlled trials (RCTs) performed in glioma patients indicate that new treatments do not improve overall survival, they have shown to prolong the period of progression-free survival. For patients, it is crucial that their level of functioning and well-being is maintained during that progression-free period. Results of our study showed that almost half of the 5539 included patients experienced a deterioration in health-related quality of life during their progression-free survival time. Only WHO performance status was found to be associated with health-related quality of life deterioration at a statistically significant and clinically relevant level, whereas allocated treatment was not independently associated with health-related quality of life deterioration during the progression-free period. In addition, we used two time-to-event models (deterioration-free survival and time-to-deterioration), that can be used to gain insight into the role of progression as a cause of HRQoL deterioration.

### Importance of the Study

Although the results of most randomized controlled trials performed in glioma patients indicate that new treatments do not improve overall survival, they have shown to prolong the period of progression-free survival. For patients, it is crucial that their level of functioning and well-being is maintained during that progression-free period, as it is important that patients can spend the limited time they have in good quality.

Although the HRQoL of glioma patients is often already impaired at diagnosis when compared to the general population, both treatment and disease progression may cause a further deterioration in HRQoL. For various stakeholders, including drug developers, regulatory agencies, and physicians, it is important to be able to understand the impact of the treatment under investigation (possible adverse effects) on the patients’ functioning and well-being, independent of the effect of the disease. In recent years, several statistical models such as time-to-event models have been proposed to better evaluate the impact of treatment on HRQoL in oncology trials. For HRQoL outcomes, the concepts “deterioration-free survival” and “time-to-deterioration” have been used to describe the time to HRQoL deterioration. In this case, deterioration-free survival reflects the time to deterioration in HRQoL, disease progression, or death, whereas the concept time-to-deterioration excludes progressive disease as an event, and thus better reflects the possible impact of the adverse effects caused by the treatment on aspects of HRQoL.

The primary aim of the current study was to determine whether the HRQoL of glioma patients can be maintained during the progression-free period. In addition, we investigated which sociodemographic and clinical factors were independently associated with a deterioration in HRQoL during the progression-free period.

### Methods

#### Study Population

This study is part of the CODAGLIO (i.e. COMbining clinical trial DAtasets in GLIoma) project, in which a database was created that included HRQoL data of individual glioma patients from previously published phase II and III RCTs (Supplementary Table 1). Sociodemographic and
clinical variables that were available in all RCTs included: tumor type (World Health Organisation [WHO] grade II or III astrocytoma, oligodendroglioma, and oligoastrocytoma [all classified as non-glioblastoma], or grade IV [classified as glioblastoma]), age, sex, disease stage (newly diagnosed versus recurrent), WHO Performance Status (PS; 0 versus 1 versus 2), and prior resection (yes versus no).

HRQoL

In all included trials, HRQoL was assessed with the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) version 3.0,14 and the EORTC brain cancer-specific QLQ-BN20.15,16 The EORTC QLQ-C30 questionnaire consists of 30 items, comprising five functional scales, three symptom scales, a global health status scale, and six single-item scales. The QLQ-BN20 consists of 20 items, comprising four symptom scales and seven single-item symptoms. Raw item scores are linearly transformed to a 0 to 100 scale.17 A clinically relevant change in HRQoL was defined as a change of ≥10 points on any scale, which is generally considered to reflect the minimum clinically important difference.18 All evaluated scales were included in the analysis. Patients who completed at least one HRQoL scale at baseline were included in the study sample.

Descriptive Statistics

Descriptive statistics were used to report HRQoL scores as well as the sociodemographic and clinical characteristics of the eligible patients. Adherence to HRQoL assessments over time was calculated as the number of forms received divided by the number of forms expected at every assessment point. Importantly, patients who completed the assessments at the time of disease progression were included in the analysis. In the included RCTs, disease progression was defined by means of the Response Assessment in Neuro-Oncology (RANO) Criteria or MacDonald criteria.19,20

Maintenance of HRQoL During the Progression-Free Period

To evaluate if HRQoL was maintained during the progression-free period, the percentage of patients with a clinically meaningful deterioration in HRQoL scores during this period (i.e., any deterioration of ≥10 points on any scale at any follow-up assessment before disease progression) was calculated both at the scale level (i.e., the percentage of patients with HRQoL deterioration per scale) and at the individual patient level (percentage of patients with HRQoL deterioration on at least one scale, considering all 26 scales simultaneously).

Factors Associated With HRQoL Deterioration

We used linear mixed models (LMMs) with a first-order factor analytic covariance structure to evaluate which factors were independently associated with HRQoL deterioration during the progression-free survival period. LMM assumptions were assessed graphically, and potential
multicollinearity was investigated with Spearman-rank correlation coefficients and Variance inflation factor (VIF) analysis. HRQoL assessments were included until the moment more than 40% of the expected HRQoL questionnaires was missing. The factors considered in the LMMs were: age, WHO PS, sex, surgery, tumor type, and allocated treatment (radiotherapy [RT monotherapy], chemotherapy [chemotherapy], radiotherapy and chemotherapy combined [RT and chemo], radiotherapy and angiogenesis inhibitors combined [RT and angio], radiotherapy combined with chemotherapy and angiogenesis inhibitors [RT and chemo and angio], chemotherapy and angiogenesis inhibitors combined [CT and angio], and chemotherapy and TFF combined [CT and TTF]). LMM results are presented for the global health scale and two commonly preselected functioning scales in the original RCTs (physical functioning and role functioning), as well as the three most prevalent symptoms in this sample. Results of the other scales are described in the Supplementary Material.

A heatmap was created to visualize the distribution of patients with and without HRQoL deterioration during their progression-free period, in relation to their sociodemographic/clinical and treatment characteristics. This heatmap allows a visual inspection of which factors were associated with a specific pattern in change in HRQoL scores during the progression-free period.

### Results

Out of the 6048 patients included in the CODAGLIO database, 5539 (91%) patients were eligible for the current study at baseline. Over time, compliance with HRQoL data dropped to 4473 (81%) for follow-up assessment 2 until 3076 (57%) for follow-up assessment 4 (Table 3). Because of the low compliance at later follow-up (<60%), analyses were truncated to follow-up assessment 4. In this subgroup, 64% of the patients were diagnosed with glioblastoma, the mean age was 54 years, and 89% of the patients had a relatively good (0 or 1) WHO PS (Table 1). The median time from randomization to progression was 7.6 months for all included patients and 8.9 months for newly diagnosed patients only. Median time from randomization to death was 17.2 and 17.9 months for all included patients and newly diagnosed patients only, respectively.

### Factors Associated With HRQoL Deterioration During the Progression-Free Period

Results of the LMMs did not indicate any multicollinearity between the included variables, and the correlation between the clinical and treatment-related variables was low to moderate (all below 0.32). Table 3 presents the estimates for the association between the selected variables and the global health status, physical functioning, and role functioning scale scores, and the three most common symptoms in this sample (fatigue, drowsiness, and motor dysfunction).

Only poor performance status (WHO PS 2 compared to WHO PS 0) showed both a statistically significant and clinically relevant association (i.e. differences ≥10 points) with HRQoL deterioration over time for the preselected and for most of the remaining exploratory HRQoL scales. Several sociodemographic and clinical characteristics were independently associated with worse HRQoL over time at a statistically significant, but not clinically
relevant level. For example, female sex (−5.8; 95% CI −6.9 to −4.7), and previous surgery (−3.6; 95% CI −5.1 to −2.1) were significantly associated with worse physical functioning over time at a statistically but not clinically relevant level (Table 3). For some scales, treatment other than radiotherapy only was associated with HRQoL deterioration at a statistically significant, but not clinically relevant level. For example, chemotherapy alone and chemotherapy and angiogenesis inhibitors were associated with physical functioning at a statistically significant but not clinically relevant level (Table 3).

Heatmap results showed no obvious pattern distinguishing patients with and without HRQoL deterioration before progression (Figure 2).

### Deterioration-Free Survival and Time-to-Deterioration

Looking at the individual trials, time-to-deterioration was significantly longer than deterioration-free survival in 85-92% of the included trials, irrespective of the assessed HRQoL scales, whereas there was no significant difference between time-to-deterioration and deterioration-free survival times in 8-15% of the trials. When combining all RCTs, median deterioration-free survival ranged from 3.8 months for fatigue to 5.4 months for seizures, and median time-to-deterioration ranged from 8.2 months for fatigue to 11.9 months for seizures (Supplementary Table 2). For all scales, time-to-deterioration was longer than deterioration-free-survival (Figure 3), and the mean difference between the two outcomes was 5.0 months in favor of time-to-deterioration. Supplementary Figure 1 shows that progression had the largest share as event in deterioration-free survival analysis (49–82%), compared with HRQoL deterioration in the absence of disease progression (9–25%) or death (8–35%). The mean proportion of progression, HRQoL deterioration in the absence of progression, and death, whichever occurred first, in the deterioration-free survival analysis for all scales was 70%, 20%, and 10% respectively.

### Table 1. Baseline Clinical and Sociodemographic Characteristics of the Included Patients

|                        | All included patients (n = 5539) | Newly diagnosed patients only (n = 4665) |
|------------------------|----------------------------------|----------------------------------------|
| Male                   | 3381 (61)                        | 2831 (61)                              |
| Female                 | 2155 (39)                        | 1832 (39)                              |
| Missing                | 3 (0)                            | 2 (0)                                  |
| Age (mean, SD)         | 54 (13)                          | 53 (13)                                |
| Glioblastoma           | 3565 (64)                        | 2845 (61)                              |
| Nonglioblastoma        | 1974 (36)                        | 1820 (39)                              |
| WHO 0                  | 2143 (39)                        | 1840 (39)                              |
| WHO 1                  | 2755 (50)                        | 2278 (50)                              |
| WHO 2                  | 615 (11)                         | 522 (11)                               |
| Missing                | 26 (0)                           | 25 (0)                                 |
| Resected               | 4033 (73)                        | 3904 (84)                              |
| Not resected           | 1348 (24)                        | 757 (16)                               |
| Missing                | 158 (3)                          | 4 (0)                                  |
| AED use                | 1271 (23)                        | 1058 (23)                              |
| Non-AED use            | 1666 (30)                        | 1583 (34)                              |
| Missing                | 2602 (47)                        | 2024 (43)                              |
| Steroid use            | 1802 (33)                        | 1685 (36)                              |
| Non-steroid use        | 2278 (41)                        | 2099 (45)                              |
| Missing                | 1459 (26)                        | 881 (19)                               |
| Allocated treatment: RT alone | 1240 (23)                        | 1267 (27)                              |
| Allocated treatment: Chemo alone | 1019 (19)                        | 626 (13)                               |
| Allocated treatment: Angio alone | 116 (2)                         | 0 (0)                                  |
| Allocated treatment: RT and chemo | 1494 (28)                        | 1531 (33)                              |
| Allocated treatment: RT and chemo and angio | 759 (14)                        | 779 (17)                               |
| Allocated treatment: Chemo and angio | 373 (7)                         | 23 (1)                                 |
| Allocated treatment: TTFields alone | 111 (2)                         | 67 (2)                                 |
| Allocated treatment: Chemo and TTFields | 427 (8)                         | 329 (7)                                |

WHO, World Health Organisation; AED, antiepileptic drugs; RT, radiotherapy; TTFields, tumor treating fields
Discussion

Using a large pooled dataset of individual HRQoL and sociodemographic/clinical data from previously conducted RCTs, the primary aim of this study was to evaluate whether glioma patients were able to maintain their level of functioning and well-being during their progression-free period. In addition, we aimed to determine which sociodemographic and clinical factors were independently associated with HRQoL deterioration during the progression-free period. First, our results showed that a small proportion of patients (9–29%) deteriorated on each specific HRQoL scale. However, when considering all scales simultaneously, we found that almost half of the patients (47%) deteriorated on at least one scale, with a mean of 5 scales. Thus, a considerable proportion of the patients experienced HRQoL deterioration during their progression-free period.

Table 2. Patients With Clinically Relevant Deteriorating HRQoL (i.e. ≥10 points) Before Progression Per Scale

| HRQoL scale                        | Number (%) of patients with a deterioration in HRQoL before progression | Median time between deterioration in HRQoL and progression in days |
|------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------|
| Global health status               | 936 (22.7)                                                             | 167                                                             |
| Physical functioning               | 965 (23.4)                                                             | 190                                                             |
| Role functioning                   | 922 (22.3)                                                             | 166                                                             |
| Emotional functioning              | 750 (18.2)                                                             | 153                                                             |
| Cognitive functioning              | 921 (22.3)                                                             | 161                                                             |
| Social functioning                 | 895 (21.7)                                                             | 151                                                             |
| Fatigue                            | 1033 (25)                                                              | 162                                                             |
| Nausea and vomiting                | 962 (23.3)                                                             | 194                                                             |
| Pain                               | 928 (22.5)                                                             | 170                                                             |
| Dyspnea                            | 784 (19)                                                               | 175                                                             |
| Insomnia                           | 805 (19.5)                                                             | 188                                                             |
| Appetite loss                      | 1011 (24.5)                                                            | 194                                                             |
| Constipation                       | 815 (19.7)                                                             | 183                                                             |
| Diarrhea                           | 603 (14.6)                                                             | 178                                                             |
| Financial difficulties             | 671 (16.3)                                                             | 175                                                             |
| Future uncertainty                 | 643 (15.6)                                                             | 135                                                             |
| Visual disorder                    | 803 (19.5)                                                             | 164                                                             |
| Motor dysfunctioning               | 922 (22.3)                                                             | 144                                                             |
| Communication deficit              | 861 (20.9)                                                             | 154                                                             |
| Hair loss                          | 725 (17.6)                                                             | 183                                                             |
| Seizures                           | 372 (9)                                                                | 169                                                             |
| Drowsiness                         | 982 (28.8)                                                             | 182                                                             |
| Headache                           | 835 (20.2)                                                             | 210                                                             |
| Itchy skin                         | 983 (23.8)                                                             | 180                                                             |
| Weakness of the legs               | 788 (19.1)                                                             | 166                                                             |
| Bladder control                    | 529 (2.8)                                                              | 147                                                             |

Days from randomization to progression minus days from randomization to deterioration in HRQoL scale. Median days from randomization to pfs = 167 days.

Next, we examined factors associated with HRQoL deterioration during this progression-free period. LMM analyses indicated that only baseline performance status was associated with a deterioration in HRQoL at a statistically significant and clinically relevant level. Compared to patients with a good performance status (WHO PS 0), those with poor performance status (WHO PS 2) had worse functioning and more symptoms at a statistically significant and also clinically relevant level. In addition to performance status, several other factors, including older age, male sex, and a diagnosis of glioblastoma, were independently associated with a deterioration in certain HRQoL scales. However, the degree of deterioration was not considered to be clinically relevant.

An important finding was that, in general, the treatment itself was not independently associated with HRQoL deterioration during the progression-free period. Our results also indicated that time-to-deterioration was longer than deterioration-free survival in the large majority (85–92%) of the included trials, suggesting the importance of disease progression as a key event driving HRQoL decline. Indeed,
in these situations, it is likely that the treatment itself did not have a negative impact on the different HRQoL aspects. In those cases where treatment had an impact on HRQoL outcomes (i.e., TTD was shorter or similar to deterioration-free survival time), the direction of the effect was not always consistent. That is, some treatment regimens had a positive impact on one HRQoL scale, and a negative impact on another scale, although typically not at a clinically relevant level. These results were not unexpected because anti-cancer treatments can simultaneously alleviate some tumor-related symptoms, while causing symptoms as side-effects of the treatment itself.

The important effect of disease progression on HRQoL outcomes is illustrated by the finding that progression was the most common event (70%) in the deterioration-free survival analyses. This finding is in line with previous research, suggesting that progression is an important factor in HRQoL deterioration in brain tumor patients. However, not all studies reporting that progression is a key event for deterioration in patients’ functioning and well-being clearly distinguished between statistically significant and clinically relevant associations, or used multivariable models investigating the independent association between progression and HRQoL outcomes.

One difficulty in the use of progression as an outcome is that the assessment of progression is difficult, with high interobserver variability, and interpretation may be confounded by pseudoprogression. Also, progression is typically a composite endpoint, reflecting both clinical deterioration and radiological progression. A growing tumor may cause clinical deterioration, as reflected in performance status, but may not yet be classified as progressive disease because radiologically it does not meet the criteria. This means that in the period where there is radiologically no (definite) sign of disease progression, the underlying disease can still have an impact on

### Table 3. Result of the Linear Mixed Model Analyses, Showing the Association Between Several Independent Variables and the Selected HRQoL Scales

| Variable                      | Global health status | Physical functioning | Role functioning | Fatigue | Drowsiness | Motor dysfunction |
|-------------------------------|----------------------|----------------------|------------------|---------|------------|------------------|
| Baseline (n = 5539)           | Ref                  | Ref                  | Ref              | Ref     | Ref        | Ref              |
| FU2 (n = 4473, 81%)           | 4.5 (4.1 to 5.6)*    | –8 (–3 to 1.9)       | –2.4 (–3.3 to –1.5)* | –2.6 (–3.6 to 4.4) | –2.3 (–3.1 to –1.6)* |
| FU3 (n = 3751, 69%)           | 9.2 (1.5)*           | –1.2 (–2.3 to –1.1)* | 2.6 (1.7 to 3.5)* | 2.5 (1.4 to 3.5)* | –9 (–1.7 to –2)* |
| FU4 (n = 3076, 57%)           | –1.0 (–1.8 to –2)    | –2 (–1.0 to 1.3)     | 1.6 (2.6 to 2.4)* | 1.6 (5.2 to 6.4)* | –6 (–1.4 to 1.5) |
| Age < 41                      | Ref                  | Ref                  | Ref              | Ref     | Ref        | Ref              |
| Age 41–64                     | –8.1 (–10.1 to –6.5)*| –8.1 (–10.2 to –6.5)*| –9.1 (–11.6 to –6.5)* | 5.9 (3.8 to 7.9)* | 3.4 (1.5 to 5.3)* | 3.7 (2.1 to 5.2) |
| Age > 64                      | –5.1 (–6.6 to –3.6)* | –3.6 (–5.1 to –2.1)* | –4.8 (–6.9 to –2.7)* | 3.2 (1.5 to 4.9)* | 6.6 (4.3 to 8.8)* | 8.1 (6.2 to 9.9)* |
| Male                          | Ref                  | Ref                  | Ref              | Ref     | Ref        | Ref              |
| female                        | –1.8 (–2.9 to –.7)*  | –5.8 (–6.9 to –4.7)* | –2.1 (–3.7 to –.6)* | 5.4 (4.1 to 6.6)* | 2.3 (1.0 to 3.7)* | 2.3 (1.1 to 3.4)* |
| Biopsy only                   | Ref                  | Ref                  | Ref              | Ref     | Ref        | Ref              |
| Surgery                       | –3.2 (–4.6 to –1.7)* | –3.6 (–5.1 to –2.1)* | –4.8 (–6.3 to –2.7)* | 3.9 (2.2 to 5.6)* | 2.2 (3.4 to 4.0)* | 5.9 (4.4 to 7.5)* |
| WHO PS 0                      | Ref                  | Ref                  | Ref              | Ref     | Ref        | Ref              |
| WHO PS 1                      | –7.7 (–8.9 to –6.6)* | –9.5 (–10.7 to –8.4)*| –12.8 (–14.5 to –11.2)* | 9.3 (7.9 to 10.6)* | 6.9 (5.5 to 8.4)* | 9.2 (8.0 to 10.4)* |
| WHO PS 2                      | –18.7 (–20.7 to –16.7)* | –28.8 (–30.8 to –26.8)* | –34.0 (–36.9 to –31.2)* | 22.3 (20.0 to 24.6)* | 17.1 (14.6 to 19.6)* | 26.3 (24.3 to 28.4)* |
| Nonglioblastoma               | Ref                  | Ref                  | Ref              | Ref     | Ref        | Ref              |
| Glioblastoma                  | –1.0 (–2.4 to 5.5)   | –1.4 (–2.8 to 1.0)   | –5 (–2.5 to 1.6)   | 2.4 (1.8 to 4.1)* | 3.4 (1.6 to 5.2)* | 1.8 (3.3 to 3.3)* |
| Treatment: RT alone           | –1 (–2.3 to 2.0)     | –3.4 (–5.6 to –1.6)* | –5 (–2.5 to 3.6)   | –3.7 (2.1)     | 1.8 (–9.4 to 4.5) | –2.7 (1.8)       |
| Treatment: CT alone           | .9 (–1.2 to 2.9)     | –1.4 (–3.5 to 7.7)   | –1.2 (–2.5 to 3.6) | –.2 (–2.2 to 2.6)* | –1.2 (–3.8 to 1.3) | –2.2 (–4.3 to 7.1)* |
| Treatment: RT and CT          | 1.2 (–1.5 to 3.8)    | .5 (–2.2 to 3.2)     | 1.5 (–2.2 to 5.3)  | –2.7 (–5.7 to 4.0) | –2.1 (–5.4 to 1.3) | –3.1 (–5.9 to –4.1)* |
| Treatment: CT and AI          | –3.4 (–6.3 to –.4)*  | –6.9 (–10.0 to –3.9)*| –5.2 (–9.4 to –9.9)* | 2.6 (–.8 to 6.1) | 3.7 (–1.1 to 7.5) | 3.2 (1.1 to 6.4) |
| Treatment: RT and TTF         | –6.7 (–10.9 to –2.6)*| –8.1 (–14.2 to –4.9)*| –9.3 (–15.2 to –3.4)* | 8.6 (3.9 to 13.4)* | 7.0 (1.8 to 12.2) | 4.6 (3.3 to 8.8)* |
| Treatment: CT and TTF         | 4.9 (2.2 to 7.6)*    | .9 (–1.8 to 3.6)     | 7.4 (3.6 to 11.2)* | –2.6 (–5.7 to 5.0) | 1.1 (–2.3 to 4.4) | –4.4 (–7.2 to –1.6)* |

*P < .05, FU, Follow-up; Ref, reference; WHO, World Health Organisation; PS, Performance status; RT, radiotherapy; CT, Chemotherapy; AI, Angiogenesis inhibitors; TTF, Tumor treating fields
aspects of HRQoL. If HRQoL would have been assessed more frequently, which is possible in clinical practice but not in clinical trials, a deterioration of HRQoL before progression may have been detected more frequently than shown in this study. This is further illustrated by post hoc analyses showing that although the median time between HRQoL deterioration and progression in days was between 135 and 210 days, a large proportion of these patients progressed within 100 days after HRQoL deterioration (Supplementary Figure 3). Further research on the role of clinical and/or radiological disease progression in HRQoL deterioration is therefore warranted.

This study revealed that a large proportion of patients experienced a clinically relevant deterioration in aspects of HRQoL during the progression-free period, and warrants attention. One important method to prevent HRQoL deterioration is routine monitoring of the patients’ functioning and well-being during the entire disease course. Routine monitoring may signal symptoms and other issues at an early stage, allowing the implementation of interventions addressing these issues. When preventing or treating symptoms, this may subsequently have a positive impact on the patients’ activities in daily life and overall quality of life. Which aspects of HRQoL are most important to a
patient (e.g. hair loss or cognitive complaints) and need an intervention, is based on the individual patients’ preferences and values and should be discussed during the consultations with the physicians. Currently, several rehabilitation programs are being developed, for example aiming at fatigue, motor symptoms, and cognitive problems, and should be considered for patients presenting with these problems.\textsuperscript{35,36} This study has several limitations that should be noted. One important limitation, which is inherent to HRQoL research in general, is missing data during follow-up. Patients with worse health status are less likely to complete questionnaires, causing attrition bias and resulting in patients with better HRQoL being overrepresented during later follow-up assessments.\textsuperscript{37} Additionally, we used a 10 points difference in HRQoL score over time to define a clinically relevant change. Although this cutoff has been used in many studies over the past decades, more recent studies suggest that this threshold may be too simplistic in that it does not distinguish between different HRQoL scales, the direction of change (improvement or deterioration), or between cancer types.\textsuperscript{38} Very recently, minimally important differences (MID) for all EORTC QLQ-C30 scales for glioma patients have been determined. Applying these MIDs, which are typically smaller than the 10-point cutoff (they range between 4 and 11 points for both within-group and between-group mean difference in change in glioma patients),\textsuperscript{39} would probably result in different median deterioration-free survival and time-to-deterioration times, and in more significant and clinically relevant associations in the linear mixed model analyses. However, because there are currently no MIDs available for the QLQ-BN20 scales, we decided to use the general 10-point cutoff in this study for all scales, including those of the EORTC QLQ-C30. Another limitation is

Fig. 3 Mean deterioration-free survival and time-to-deterioration in months per HRQoL scale when all included trials combined.
that not all patients in the included studies were assessed at the exact same time points with respect to the HRQoL and radiological assessments, as the duration of the intervals of assessment differed across trials (Supplementary Table 3 and Supplementary Figure 4). Since the calculation of deterioration-free survival and time-to-deterioration periods depends on the timing of these assessments, the obtained estimates may therefore be biased, as patients between trials may not be comparable. Moreover, since the timing of the HRQoL and radiological assessments is largely similar, (large) differences in the duration of TTD and deterioration-free survival are also difficult to establish in clinical trials. In daily clinical practice, where HRQoL could be monitored more frequently than radiological assessment, differences may be more significant.

In conclusion, this study suggests that almost half of the patients with glioma will experience a clinically relevant deterioration in at least one HRQoL scale during their progression-free period. While extending the progression-free period is certainly important, it is most meaningful if the patients’ HRQoL is relatively good during that period. In general, treatment was not found to be independently associated with a clinically relevant deterioration in HRQoL during the progression-free period.

Supplementary Material

Supplementary material is available at Neuro-Oncology online.

Keywords

brain tumor | deterioration-free-survival | progressive disease | time-to-deterioration

Funding

This work was supported by a grant from The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group [RP 1515].

Conflict of interest statement. ABo received research grants from Roche, Genentech and Boeringer-Ingelheim, outside the submitted work; AAB received travel grant to ASCO from Roche and Celgene, outside the submitted work; OC has received research grants from Roche, and honoraria for lectures or advisory board from Celldex, Immatics, Abbvie and Servier, outside the submitted work; UH received grants and personal fees from Roche, personal fees and non-financial support from Medac and Bristol-Myers Squibb, and personal fees from Novocure, Novartis, Daichii-Sankyo, Riemsor and Noxxon, outside the submitted work; WW received study drug from Apogenex, Pfizer and Roche as well as compensation for advisory activities to Abbvie and Roche, outside the submitted work; all other authors reported no conflict of interest.

Authorship statement. BB, MB, AAB, OC, UH, FKG, AM, RS, MW and WW were the principal investigators of the RCTs for which the data was originally collected, and were involved in data collection. In addition, JR and MT were also involved in data collection in several RCTs. All authors were involved in the conceptualization of this study. MC and LD performed the statistical analysis and wrote the first draft of the manuscript. All authors have been involved in the revision of the manuscript and have read and approved the final version.

References

1. Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4(9):1254–1262.
2. Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954–1963.
3. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–350.
4. Keime-Guibert F, Chinot O, Taillandier L, et al. Phase 3 study comparing radiotherapy with supportive care in older patients with newly diagnosed anaplastic astrocytomas (AA) or glioblastoma multiforme (GBM): an ANOCEF group trial. Neuro Oncol. 2005;7(6):349–349.
5. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28(4):334–340.
6. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–953.
7. Reijneveld JC, Taphoorn MJB, Coens C, et al. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1533–1542.
8. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomised clinical trial. JAMA Oncol. 2018;4(4):495–504.
9. Dirven L, van den Bent MJ, Bottomley A, et al.; Dutch Neuro-Oncology Group (LWNO). The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer. 2015;51(10):1321–1330.
10. Taphoorn MJ, Henriksson R, Bottomley A, et al. Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol. 2015;33(19):2166–2175.
11. Taphoorn MJ, van den Bent MJ, Mauer ME, et al.; European Organisation for Research and Treatment of Cancer. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007;25(36):5723–5730.
12. Bonnetain F, Dahan L, Maillard E, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment
trials in patients with metastatic pancreatic adenocarcinoma. *Eur J Cancer*. 2010;46(15):2753–2762.

13. Hamidou Z, Babakuye TS, Mercier M, et al. Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer. *Oncologist*. 2011;16(10):1458–1468.

14. Aaronson NK, Ahmadzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993;85(5):365–376.

15. Taphoorn MJ, Claassen L, Aaronson NK, et al.; EORTC Quality of Life Group, and Brain Cancer, NCIC and Radiotherapy Groups. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. *Eur J Cancer*. 2010;46(6):1033–1040.

16. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. *Qual Life Res*. 1996;5(1):139–150.

17. Fayers PM, Aaronson NK, Bjorndal K, Groenvold M, Curran D, Bottomley A. EORTC Quality of Life Group. EORTC QLQ-C30 Scoring Manual. Brussels, Belgium: EORTC Data Center; 2001.

18. Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. *Eur J Cancer*. 2012;48(11):1713–1721.

19. Macdonald DR, Cascino TL, Schold SC Jr, Caimcross JG. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol*. 1990;8(7):1277–1280.

20. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro- oncology working group. *J Clin Oncol*. 2010;28(11):1963–1972.

21. Link CL. Confidence intervals for the survival function using Cox’s proportional-hazard model with covariates. *Biometrics*. 1984;40(3):601–609.

22. IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20. Armonk, NY: IBM Corp; 2013.

23. Team R. *RStudio: Integrated Development for R*. Boston, MA: RStudio, Inc; 2015; 42.14. https://www.rstudio.com.

24. Coomans MB, Dirven L, Aaronson NK, et al. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? *Neuro Oncol*. 2019;21(11):1447–1457.

25. Yavas C, Zorlu F, Özüyigit G, et al. Health-related quality of life in high-grade glioma patients: a prospective single-center study. *Support Care Cancer*. 2012;20(10):2315–2325.

26. Bosma I, Reijneveld JC, Douw L, et al. Health-related quality of life of long-term high-grade glioma survivors. *Neuro Oncol*. 2009;11(1):51–58.

27. Yavas C, Zorlu F, Özüyigit G, et al. Health-related quality of life in high-grade glioma patients: a prospective single-center study. *Support Care Cancer*. 2012;20(10):2315–2325.

28. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. *Br J Cancer*. 2000;83(5):588–593.

29. Dirven L, Reijneveld JC, Taphoorn MJB, et al. Impact of radiation target volume on health-related quality of life in patients with low-grade glioma in the 2-year period post treatment: a secondary analysis of the EORTC 22033-26033. *Int J Radiat Oncol Biol Phys*. 2019;104(1):90–100.

30. Provenzale JM, Ison C, Delong D. Bidimensional measurements in brain tumors: assessment of interobserver variability. *AJR Am J Roentgenol*. 2009;193(6):W515–W522.

31. Brandsma D, Stalpers L, Taal W, Smirn P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. *Lancet Oncol*. 2008;9(5):453–461.

32. Ellingston BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. *Neurotherapeutics*. 2017;14(2):307–320.

33. Luckett T, Butow P, King M. Improving patient outcomes through the routine use of patient-reported data in cancer clinics: future directions. *Psycho Oncol*. 2009;18(11):1129–1138.

34. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. *J Clin Oncol*. 2016;34(6):557–565.

35. van der Linden SD, Sitskoorn MM, Rutten GM, Gehring K. Study protocol for a randomized controlled trial evaluating the efficacy of an evidence-based iPad-app for cognitive rehabilitation in patients with primary brain tumors. *Neurosurgery*. 2019;85(2):273–279.

36. Hansen A, Pedersen CB, Jarden JO, Beier D, Minet LR, Søgaard K. Effectiveness of physical therapy- and occupational therapy-based rehabilitation in people who have glioma and are undergoing active anticancer treatment: single-blind, randomized controlled trial. *Phys Ther*. 2020;100(3):564–574.

37. Dirven L, Reijneveld JC, Aaronson NK, Bottomly A, Uitdehaag BM, Taphoorn MJ. Health-related quality of life in patients with brain tumors: limitations and additional outcome measures. *Curr Neurol Neurosci Rep*. 2013;13(7):359.

38. Musoro JZ, Hamel JF, Ediebaeh DE, et al.; EORTC Quality of Life Group. Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. *BMJ Open*. 2018;8(1):e019117.

39. Dirven L, Musoro JZ, Coens C, et al. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. *Neuro Oncol*. 2021;23(8):1327–1336.